Cargando…
Current international trends in the treatment of multiple sclerosis in children—Impact of the COVID-19 pandemic
BACKGROUND: Only recently has the first disease-modifying therapy been approved for children with multiple sclerosis (MS) and practice patterns including substantial off-label use have evolved. Understanding attitudes towards treatment of paediatric MS and whether this has changed due to the ongoing...
Autores principales: | Sandesjö, Fredrik, Wassmer, Evangeline, Deiva, Kumaran, Amato, Maria Pia, Chitnis, Tanuja, Hemingway, Cheryl, Krupp, Lauren, Pohl, Daniela, Rostasy, Kevin, Waubant, Emanuelle, Banwell, Brenda, Wickström, Ronny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474759/ https://www.ncbi.nlm.nih.gov/pubmed/34624643 http://dx.doi.org/10.1016/j.msard.2021.103277 |
Ejemplares similares
-
Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG
por: Waubant, Emmanuelle, et al.
Publicado: (2019) -
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
por: Deiva, Kumaran, et al.
Publicado: (2020) -
Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study
por: Krupp, Lauren, et al.
Publicado: (2022) -
Preventing Multiple Sclerosis: The Pediatric Perspective
por: Hardy, Duriel, et al.
Publicado: (2022) -
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020)